Close

VNDA Financial Facts

Research and development: 7.29M
Cost of sales, product: 6.99M
See Full Income Statement

Cash and cash equivalents: 32.77M
Total current liabilities: 50.68M
See Full Balance Sheet

Vanda Pharma (VNDA) Earnings

  |   Expand Research on VNDA
Next EPS Date 5/1/24 EPS Growth Rate -233.3%
Average EPS % Beat Rate +35.8% Revenue Growth Rate +59,101.9%
Average % Move 1-Wk after EPS -3.7% Normal Earnings Time After Close
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
5/1/24 Q124 N/A-$0.08 N/A N/A$37M N/A N/A N/A
2/7/24 Q423 -$0.04-$0.09 +$0.05$45.27M$37M N/A Details
11/1/23 Q323 N/A-$0.04 N/A N/A$44.5M N/A N/A N/A
11/8/23 Q323 $0.00-$0.04 +$0.04$38.82M$44.5M N/A Details
7/27/23 Q223 $0.03$0.08 -$0.05$46.06M$62M N/A Details
5/3/23 Q123 $0.06N/A N/A $62.5KN/A N/A Details
2/8/23 Q422 $0.12$0.08 +$0.04$64.5M$67.6M N/A Details
11/2/22 Q322 $0.14$0.11 +$0.03$70.1M$67.9M = Details